Sagittarius Life Science

Sagittarius Life Science EBIT Margin

The EBIT Margin (Operating Margin) of Sagittarius Life Science (3205.TWO) as of Oct 31, 2026 is -16.91 %. In the previous year, EBIT Margin (Operating Margin) was -13.16 % — a change of 28.45% (lower).

EBIT Margin

-16.91 %

YoY

28.45%

Last updated:

EBIT Margin (Operating Margin) of Sagittarius Life Science is 2025 -16.91 % . EBIT Margin (Operating Margin) of Sagittarius Life Science was 2024 -13.16 % . It decreases by 28.45% lower compared to the previous year.

Sagittarius Life Science's operating (EBIT) margin stands at -16.9%, down from -14.8% several years earlier.

The Sagittarius Life Science EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-27.86 TWD
Jan 1, 2019
-23.96 TWD
Jan 1, 2020
-13.20 TWD
Jan 1, 2021
-14.82 TWD
Jan 1, 2022
-14.42 TWD
Jan 1, 2023
-12.88 TWD
Jan 1, 2024
-13.16 TWD
Jan 1, 2025
-16.91 TWD
The Sagittarius Life Science EBIT Margin history
YEAREBIT MarginYoY
-16.91 %+28.45%
-13.16 %+2.16%
-12.88 %-10.63%
-14.42 %-2.72%
-14.82 %+12.27%
-13.20 %-44.91%
-23.96 %-14.02%
-27.86 %+56.73%
-17.78 %-168.70%
25.88 %+6.41%
24.32 %+5,958.07%
0.40 %-521.62%
-0.10 %-479.61%
0.03 %-116.52%
-0.15 %+3.19%
-0.15 %-19.69%
-0.18 %-91.83%
-2.24 %-79.03%
-10.69 %+103.09%
-5.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sagittarius Life Science Stock analysis

What does Sagittarius Life Science do? Sagittarius Life Science Corp. generates revenue through the manufacture and sale of Chinese and western medicine, including nutrition and health formulations, natural and organic food, beverages, probiotic fermentation products, beauty care ingredients, Chinese herbal medicines, plant new medicines, and health supplies. The company serves domestic markets in Taiwan and overseas markets in Asia and the Americas, distributing its products through established channels. Technical services for pharmaceutical R&D are also a key revenue stream, supporting clients in developing both traditional and modern medicine solutions. The firm's product portfolio targets health-conscious consumers seeking natural and organic solutions, as well as businesses in the pharmaceutical and beauty care industries requiring specialized ingredients and formulations. Domestic sales focus on Taiwan, while international distribution extends to Asian regions outside of Taiwan and the Americas, reflecting a strategic market expansion. Revenue is derived from direct product sales and technical service contracts, with no mention of third-party partnerships or additional revenue streams beyond the described offerings. Sagittarius Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sagittarius Life Science stock

EBIT Margin (Operating Margin) of Sagittarius Life Science is -16.91 % in 2025.

EBIT Margin (Operating Margin) of Sagittarius Life Science changed from -13.16 % to -16.91 %, representing a 28.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Sagittarius Life Science since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Sagittarius Life Science with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sagittarius Life Science

All Key Metrics — Sagittarius Life Science